(CercleFinance.com) – Novo Nordisk announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency had adopted a positive opinion, recommending the marketing authorization of Awiqli ( the brand name icodec basal insulin once a week) for the treatment of diabetes in adults.
The positive opinion from the CHMP is based on a phase 3a trial which showed that icodec basal insulin administered once a week achieved a greater reduction in blood glucose as well as a greater time spent in the recommended range blood glucose levels compared to daily basal insulin in people with type 2 diabetes.
‘We believe that by reducing the number of basal insulin injections from seven to once per week, Awiqli has the potential to have a significant impact and improve the treatment of people living with diabetes,’ said Martin Holst Lange, executive vice president of development at Novo Nordisk.
Novo Nordisk expects to receive final marketing authorization from the European Commission within approximately two months.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
